AIM ImmunoTech Inc (NYSE American:AIM)

2.06
Delayed Data
As of May 07
 0.00 / 0.00%
Today’s Change
1.60
Today|||52-Week Range
4.30
+15.08%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$101.9M

Company Description

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Contact Information

AIM ImmunoTech, Inc.
2117 SW Highway 484
Ocala Florida 34473
P:(352) 448-7797
Investor Relations:

Employees

Shareholders

Mutual fund holders6.23%
Other institutional1.41%
Individual stakeholders1.13%

Top Executives

Thomas Kenwood EquelsExecutive Vice Chairman, President & CEO
Peter W. RodinoCOO, Secretary & General Counsel
Ellen M. LintalChief Financial Officer
David R. StrayerChief Scientific & Medical Officer